Department of Interventional Neuroradiology, Beijing Neurosurgical Institute; Beijing Tiantan Hospital, Capital Medical University, China.
Curr Neurovasc Res. 2014 Feb;11(1):16-22. doi: 10.2174/1567202610666131210104606.
Timing of treatment of aneurysmal subarachnoid hemorrhage has been controversial. This retrospective study was designed to access the safety and efficacy among cohorts of different timing of endovascular treatment patients with aneurysmal subarachnoid hemorrhage. A database of patients with aneurysmal subarachnoid hemorrhage was analyzed who were confirmed by CT, and underwent endovascular treatment between January 2005 and January 2012,. The patients were grouped into four cohorts according to the timing of treatment: ultra-early cohort (within 24 hours of onset which was confirmed by CT), early cohort (between 24 and 72 hours of onset which was confirmed by CT), intermediate cohort (between 4 and 10 days of onset which was confirmed by CT) and delayed cohort (after 11 days of onset which was confirmed by CT). Patient demographics, aneurysms features and clinical outcomes were analyzed to evaluate safety and efficacy for timing of endovascular treatment among four cohorts. In our series of 664 patients, 269 patients were grouped into ultra-early cohort, 62 patients in early cohort, 218 patients in intermediate cohort, and 115 patients in delayed cohort. The patient demographics, aneurysm characteristics and neurological conditions on admission among groups showed no statistical significance. As a result of the 9-month follow-up with 513 patients, good outcome (mRS<2) was achieved in 78% patients in "ultra-early" cohort compared with that of 57% in the "intermediate" group(p=0.000), whereas other comparisons showed no statistical significance(p<0.05) among the four groups. Dividing the patients with dichotomized mRS into "good outcome" group and "poor outcome" group (mRS<2) at the 9-month follow-up, the results showed lower Hunt-Hess scores (p=0.000) and smaller size of aneurysms (p=.001) which were correlated with the good outcome. Hypertension (p=0.776), age (p=0.327), sex (p=0.551) and location (p=0.901) showed no statistical significance between groups. Endovascular treatment of aneurysmal subarachnoid hemorrhage which was confirmed by CT within 72 hours achieved better outcomes than that confirmed after 72 hours, especially in those patients treated within 24 hours of onset in comparison with patients treated between 4 and 10 days.
治疗颅内动脉瘤性蛛网膜下腔出血的时间一直存在争议。本回顾性研究旨在评估不同时间窗血管内治疗颅内动脉瘤性蛛网膜下腔出血患者的安全性和疗效。通过 CT 证实,对 2005 年 1 月至 2012 年 1 月期间接受血管内治疗的颅内动脉瘤性蛛网膜下腔出血患者的数据库进行了分析。根据治疗时间将患者分为四组:超早期组(发病 24 小时内,通过 CT 证实)、早期组(发病 24-72 小时内,通过 CT 证实)、中期组(发病 4-10 天内,通过 CT 证实)和延迟组(发病 11 天后,通过 CT 证实)。分析患者的人口统计学特征、动脉瘤特征和临床结局,以评估四组患者血管内治疗时机的安全性和疗效。在我们的 664 例患者系列中,269 例患者归入超早期组,62 例患者归入早期组,218 例患者归入中期组,115 例患者归入延迟组。各组患者的人口统计学特征、动脉瘤特征和入院时的神经状况无统计学意义。在对 513 例患者进行 9 个月随访后,超早期组 78%的患者获得良好结局(mRS<2),而中期组仅为 57%(p=0.000),其他组间比较无统计学意义(p<0.05)。在 9 个月随访时,将 mRS 分为二分类的“良好结局”组和“不良结局”组(mRS<2),结果显示较低的 Hunt-Hess 评分(p=0.000)和较小的动脉瘤体积(p=0.001)与良好结局相关。高血压(p=0.776)、年龄(p=0.327)、性别(p=0.551)和位置(p=0.901)在各组间无统计学意义。CT 证实发病后 72 小时内进行血管内治疗的颅内动脉瘤性蛛网膜下腔出血的结局优于发病后 72 小时后的治疗,尤其是在发病后 24 小时内治疗的患者与在发病后 4-10 天治疗的患者相比。